Oregon Public Employees Retirement Fund Buys 681 Shares of PRA Health Sciences Inc (NASDAQ:PRAH)

Oregon Public Employees Retirement Fund lifted its stake in PRA Health Sciences Inc (NASDAQ:PRAH) by 2.9% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 23,878 shares of the medical research company’s stock after acquiring an additional 681 shares during the quarter. Oregon Public Employees Retirement Fund’s holdings in PRA Health Sciences were worth $2,368,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in PRAH. Fagan Associates Inc. lifted its holdings in PRA Health Sciences by 1.8% during the second quarter. Fagan Associates Inc. now owns 19,725 shares of the medical research company’s stock valued at $1,956,000 after purchasing an additional 355 shares in the last quarter. NN Investment Partners Holdings N.V. lifted its holdings in PRA Health Sciences by 4.9% during the second quarter. NN Investment Partners Holdings N.V. now owns 860,469 shares of the medical research company’s stock valued at $85,316,000 after purchasing an additional 40,436 shares in the last quarter. Handelsbanken Fonder AB purchased a new position in PRA Health Sciences during the second quarter valued at approximately $278,000. Campbell & CO Investment Adviser LLC lifted its holdings in PRA Health Sciences by 25.5% during the second quarter. Campbell & CO Investment Adviser LLC now owns 7,946 shares of the medical research company’s stock valued at $788,000 after purchasing an additional 1,617 shares in the last quarter. Finally, Scout Investments Inc. lifted its holdings in PRA Health Sciences by 65.9% during the second quarter. Scout Investments Inc. now owns 101,477 shares of the medical research company’s stock valued at $10,061,000 after purchasing an additional 40,318 shares in the last quarter. Hedge funds and other institutional investors own 99.75% of the company’s stock.

Several equities analysts have weighed in on PRAH shares. BidaskClub raised shares of PRA Health Sciences from a “hold” rating to a “buy” rating in a report on Wednesday, July 24th. ValuEngine cut shares of PRA Health Sciences from a “buy” rating to a “hold” rating in a research report on Saturday, April 13th. Svb Leerink reiterated a “market perform” rating on shares of PRA Health Sciences in a research report on Tuesday, July 2nd. Mizuho set a $100.00 price objective on shares of PRA Health Sciences and gave the company a “hold” rating in a research report on Friday, May 3rd. Finally, Leerink Swann initiated coverage on shares of PRA Health Sciences in a research report on Tuesday, July 2nd. They set a “market perform” rating and a $105.00 price objective on the stock. Eight equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $113.40.

Shares of PRA Health Sciences stock traded up $3.26 on Friday, hitting $96.76. 1,588,823 shares of the company traded hands, compared to its average volume of 398,021. The firm has a market cap of $6.56 billion, a PE ratio of 24.62, a P/E/G ratio of 1.35 and a beta of 1.12. The company has a quick ratio of 0.90, a current ratio of 0.90 and a debt-to-equity ratio of 1.12. PRA Health Sciences Inc has a 52 week low of $82.12 and a 52 week high of $121.98. The company’s 50-day moving average price is $98.47.

PRA Health Sciences (NASDAQ:PRAH) last released its quarterly earnings data on Wednesday, July 31st. The medical research company reported $1.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.11 by $0.11. The firm had revenue of $763.31 million for the quarter, compared to analysts’ expectations of $764.95 million. PRA Health Sciences had a net margin of 5.39% and a return on equity of 27.37%. The company’s revenue for the quarter was up 5.6% compared to the same quarter last year. During the same quarter last year, the business posted $1.00 earnings per share. As a group, research analysts anticipate that PRA Health Sciences Inc will post 4.63 earnings per share for the current year.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

Recommended Story: What is the Ex-Dividend Date in Investing?

Want to see what other hedge funds are holding PRAH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PRA Health Sciences Inc (NASDAQ:PRAH).

Institutional Ownership by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.